Abdominal Obesity Linked to Prevalence, Severity of Menopausal Symptoms
via HealthDayWEDNESDAY, May 13, 2026 -- Abdominal obesity (AO) is associated with a higher prevalence and greater severity of menopausal symptoms, according to a study published online May 5 in Menopause.
Diya Wang, from the Shantou University Medical College in China, and colleagues conducted a cross-sectional analysis involving 1,150 women from visit 6 of the study of Women's Health Across the Nation to compare menopausal symptom networks between women with and without AO, defined as a waist-to-height ratio ≥0.5.
The researchers found that women with AO reported a higher prevalence and greater severity of several symptoms. The AO group had marginally higher network density (0.59; 46 of 78 edges) compared with the non-AO group (0.55; 43 of 78 edges). Significant differences in network structure were seen using the Network Comparison Test, while global strength was comparable. There was a difference observed in core symptoms based on AO status: Forgetfulness, irritability, and night sweats showed the highest centrality in the AO group, while night sweats, palpitations, and depression showed the highest centrality in the non-AO group. The groups also differed in terms of symptom clusters.
"Educating women early about healthy lifestyle interventions to prevent midlife weight gain is key to improving mental and physical well-being during a tumultuous time frame," Monica Christmas, M.D., associate medical director for The Menopause Society, said in a statement.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2026-05-14 02:49
Read more
- Clinical Trial Finds No Difference in Fluid Treatment Options for Pediatric Sepsis
- FDA Approves Auvelity for Alzheimer Disease-Related Agitation
- ASMBS: 2020 to 2024 Saw Drop in Number of Metabolic, Bariatric Surgeries
- FDA Green Lights Expanded Access to Pancreatic Cancer Drug, Daraxonrasib
- Partner Therapeutics Announces Receipt of FDA Commissioner’s National Priority Voucher for Bizengri (zenocutuzumab-zbco) in NRG1 Fusion-Positive Cholangiocarcinoma
- Meat Consumption Rises as Protein Trend Grows, Experts Warn
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions